Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
92 hedge funds and large institutions have $211M invested in Concert Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 43 reducing their positions, and 8 closing their positions.
1,195% more call options, than puts
Call options by funds: $259K | Put options by funds: $20K
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
1% more funds holding
Funds holding: 91 → 92 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.22% less ownership
Funds ownership: 72.53% → 72.31% (-0.22%)
2% less capital invested
Capital invested by funds: $214M → $211M (-$3.22M)
51% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.82M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.96M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$985K |
| 4 |
LC
L1 Capital
Melbourne VIC 3000,
Australia
|
+$807K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$505K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.85M |
| 2 |
Millennium Management
New York
|
-$1.75M |
| 3 |
QI
QS Investors
New York
|
-$1.54M |
| 4 |
EP
Eversept Partners
New York
|
-$1.27M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$576K |
CNCE Hedge Fund Activity: Q3 2020 in Review
92 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q3 2020, worth a combined $211M — down 1.5% from $214M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CNCE positions and 8 closed out — a net gain of 1 holder — while 21 added to existing stakes and 43 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $5.82M. The largest seller was Sphera Funds Management, cutting an estimated $3.85M.
- 92 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q3 2020, up from 91 in Q2 2020.
- Funds reported $211M of Concert Pharmaceuticals, Inc. stock for Q3 2020, down 1.5% quarter-over-quarter.
- 9 funds opened new Concert Pharmaceuticals, Inc. positions in Q3 2020 and 8 closed out, a net change of +1 holder.
- The largest Concert Pharmaceuticals, Inc. buyer in Q3 2020 was Point72 Asset Management, an estimated $5.82M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q3 2020 was Sphera Funds Management, an estimated $3.85M sold.
Based on aggregated 13F filings for Q3 2020.